FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia
FDA approves new drug Crysvita for rare bone diseases in children and adults.
FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) in patients 6 months and older and for tumor-induced osteomalacia (TIO…
The FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It is the first treatment th…
Burosumab improved clinical and biochemical outcomes in patients with tumor-induced osteomalacia.
Can a new drug help patients with tumor-induced bone loss before surgery?
This hybrid study, combining a clinical survey with a systematic review, evaluated burosumab in patients with tumor-induced osteomalacia. Cl…
A new drug helps patients with tumor-induced bone loss improve health and blood chemistry while waiting for surgery or if surgery isn't poss…